Journal
FRONTIERS IN MEDICINE
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2022.940644
Keywords
pregnancy; pharmacokinetics; clinical trials; regulatory; ADME
Categories
Funding
- Bill & Melinda Gates Foundation, Seattle, Washington, United States
Ask authors/readers for more resources
Pregnancy-related physiological changes can affect the safety and effectiveness of medicines, highlighting the need for pharmacokinetic data to support dose adjustments. Currently, there is limited research data available, emphasizing the urgency for more high-quality data collection. Additionally, clinical study methodology can impact the usefulness of the data.
Pregnancy-related physiological changes can alter the absorption, distribution, metabolism and excretion of medicines which may affect the safety and efficacy of the medicines administered in pregnancy. Pharmacokinetic data can thus be instrumental in supporting dose adjustments required in this population. This review considers the availability of published pharmacokinetic data for over 200 medicines of interest for use in pregnancy in the UK, to identify whether sufficient data currently exists, in principle, for any medicine or group of medicines to support dose adjustments to maintain maternal health through pregnancy. Very limited data was found for many of the medicines of interest. Nevertheless, well documented, large changes of exposure for some drugs, where data is available, highlights the urgent need to collect more data of good quality to inform appropriate doses, when needed, in this population. In addition, clinical study methodology can have an impact on the usefulness of the data and key clinical design aspects are highlighted for consideration in future clinical study design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available